Introducing Less Invasive Ventricular Enhancement (LIVE®)

  • Remodel Heart Failure
  • Regain Function
  • Renew Life

About Us

BioVentrix, Inc. is a privately held medical device company headquartered in Mansfield, MA, USA, focused on the development of less invasive therapies to treat the failing left ventricle, the most common cause of heart failure. BioVentrix technologies aim to improve cardiac function by directly addressing left ventricular dilation.

Less Invasive Ventricular Enhancement or LIVE® is a revolutionary procedure which offers a new treatment option for patients suffering from ischemic cardiomyopathy. The Revivent TC® TransCatheter Ventricular Enhancement System is a safer and less invasive alternative to surgical ventricular remodeling. It was developed for the purpose of excluding discrete left ventricular scar, thereby reconfiguring abnormal cardiac geometry that leads to dysfunction. Our unique system provides a new solution for multidisciplinary heart teams and their patients by its proven clinical improvements.

Our Management Team

With a 30-year career rooted in heart failure, structural heart, interventional cardiology and cardiac surgery, and proven success in fundraising, corporate strategy, market development and physician relationship-building, Jim Dillon serves as President and CEO of BioVentrix. He joined the company in April 2021, with the goal of building the company into a high-performance heart failure therapy company. Prior to joining BioVentrix, he co-founded Reprieve Cardiovascular, an innovator in therapy for acute decompensated heart failure (ADHF), and served as its CEO and as a Board Director. Under his leadership, the company completed first-in-human clinical, achieved FDA Breakthrough Therapy Designation, and secured Series A financing. Previously, he held a series of leadership positions in corporate strategy and sales at St. Jude Medical, driving market development, new technology adoption, capital/consumable sales strategies, and high-performance commercial teams. Prior to St. Jude Medical, Jim held senior executive sales and marketing positions with Abiomed, as well as, was a key contributor to several start-ups’ acquisition and exits; VNUS Medical Technologies (acquired by Covidien), Perclose (acquired by Abbott), Heart Technologies Inc. (acquired by Boston Scientific), and Devices for Vascular Intervention (acquired by Eli Lilly).

William R. Abbott has served as our Chief Financial Officer since July 2019. Mr. Abbott has more than thirty years of experience in multi-industry international companies. Prior to joining us, Mr. Abbott was the Senior Vice President and Chief Financial Officer, Treasurer and Secretary of Hancock Jaffe Laboratories, Inc. from 2016 to 2018; where he successfully took the company through an IPO and listing on NASDAQ. Mr. Abbott was also the Interim President from July 2016 to September 2017. Mr. Abbott served as Vice President of Finance and Corporate Controller and later as Interim Chief Financial Officer of Apollo Medical Holdings, Inc. From 2011 to 2014, he was an independent consultant providing accounting and advisory services. From 2006 to 2011, Mr. Abbott served as Senior Vice President, Chief Financial Officer, Secretary and Treasurer for Cardiogenesis Corporation; where he led a successful sale of the company to CryoLife. From 1997 to 2005, Mr. Abbott served in financial management positions at Newport Corporation, including as Vice President of Finance and Treasurer from 2001 to 2005 and Vice President and Corporate Controller from 1997 to 2001; where he was responsible for 8 aggregate acquisitions for $700M. Prior to that, Mr. Abbott served as Vice President and Corporate Controller of Amcor Sunclipse North America, Director of Financial Planning at Coca-Cola Enterprises, Inc. and Controller of McKesson Water Products Company. Mr. Abbott also spent six years in management positions at PepsiCo, Inc. after beginning his career with PricewaterhouseCoopers, LLP.

Mr. Abbott has a Bachelor of Science degree in accounting from Fairfield University and a Master’s in Business Administration degree from Pepperdine University.

Steve Chartier joined BioVentrix in December 2021 as the company’s Chief Operating Officer (COO), bringing with him over 25 years of proven senior leadership experience managing global regulatory strategy, clinical development, and operations for emerging and established medical device and biotechnology companies. Before joining the Company, Mr. Chartier served as Vice President of Global Clinical Affairs at Sirtex Medical Limited, designing and executing clinical studies and clinical operations for a leading manufacturer of target liver cancer therapies. Prior to this time, he served as the CEO and President at Cardiovascular Clinical Sciences Foundation, a prominent CRO providing clinical trial management for cardiovascular studies. Previously, Mr. Chartier served as the Vice President of Regulatory, Quality and Clinical Affairs at Anika Therapeutics directing clinical development and global regulatory channels. Mr. Chartier also served as Chief Operating Officer for Infraredx, Inc. for many years leading the global regulatory, quality, manufacturing and clinical development strategy for a novel cardiac intravascular imaging technology mapping coronary artery disease.

Dr. Ben-Yehuda joined BioVentrix in 2023 as the company’s Chief Medical Officer. He is a distinguished clinical cardiologist and clinical trialist with more than 25 years’ experience in the treatment of cardiac patients with coronary disease, myocardial infarction, and heart failure. He is currently Professor of Medicine, University of California, San Diego (UCSD). He is also the Editor-in-Chief of Coronary Artery Disease and Deputy Editor of Structural Heart: The Journal of the Heart Team, both peer-reviewed journals.

Previously, Dr. Ben-Yehuda was the Executive Director of the Clinical Trials Center (CTC) at the Cardiovascular Research Foundation (CRF), one of the world’s leading nonprofit organizations specializing in interventional cardiology innovation, research, and education, and Vice President, Cardiovascular Clinical Trials, at Gilead Sciences.

Dr. Ben-Yehuda has personally authored and co-authored over 200 peer-reviewed publications and is the recipient of multiple awards including Top Abstract, TCT Conference 2017, UCSD Department of Medicine Teaching Awards, and Sackler Faculty Prize for Excellence for his MD Thesis.

Our Board of Directors

  • Ray Cohen – Chairman of the Board, BioVentrix – CEO and Member of the Board of Directors, Axonics Modulation Technologies, Inc.
  • Bihua Chen – CEO and Portfolio Manager, Cormorant Asset Management
  • Professor Andrew Coats – President, Heart Failure Association of the ESC
  • Jim Dillon – President and CEO, BioVentrix, Inc.
  • Andrew Hinson – Member of the Board of Directors, BioLife Solutions, Inc.
  • David Richmond – Founding Partner and Chairman, Richmond Brothers, Inc.
  • Rinda Sama – Chief Operating Officer, Axonics Modulation Technologies, Inc.
  • Mike Taglich – Taglich Brothers Investment Banking
  • Raphael Wisniewski – Partner, Andera Partners